Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283411 | 1.00 | ALOX15 (0.48) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL282020 | 0.89 | ALOX15 (0.55) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL23230056 | 0.86 | ALOX15 (0.50) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL68996 | 0.86 | ALOX15 (0.43) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL29446755 | 0.83 | ALOX15 (0.55) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL1146850 | 0.83 | ALOX15 (0.55) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL6743198 | 0.83 | ALOX15 (0.40) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL30573016 | 0.79 | ALDH1A1 (0.46) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL18262903 | 0.79 | ALDH1A1 (0.46) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL47929 | 0.78 | ALDH1A1 (0.61) | ALOX15ALOX12CYP3A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
| CN-118251383-A | Macrocyclic compounds as proteasome beta subunit type 5 inhibitors | 利德探索中心有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024023585-A2 | UROLITHIN DERIVATIVES AND THERAPEUTIC USES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4301736-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2024-01-10 | — | — | EP | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| EP-2757113-A2 | Catalysts, processes for making catalysts, processes for making polyolefin compositions and polyolefin compositions | Dow Global Technologies LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8592615-B2 | Catalysts, processes for making catalysts, processes for making polyolefin compositions, and polyolefin compositions | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2411424-A2 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS AND POLYOLEFIN COMPOSITIONS | Dow Global Technologies LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010102163-A2 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS AND POLYOLEFIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102163-A2 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS AND POLYOLEFIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227990-A1 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS, AND POLYOLEFIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227990-A1 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS, AND POLYOLEFIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227990-A1 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS, AND POLYOLEFIN COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALOX12 4450/4885CYP3A4 4548/4885 |
| US-20100227990-A1 | CATALYSTS, PROCESSES FOR MAKING CATALYSTS, PROCESSES FOR MAKING POLYOLEFIN COMPOSITIONS, AND POLYOLEFIN COMPOSITIONS | FDFT1, PARG, CPSF6 | ALOX15 58/4885ALOX12 85/4885CYP3A4 1739/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ALOX15 694/4885ALOX12 804/4885CYP3A4 685/4885 |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | ALOX15 1921/4885ALOX12 3166/4885CYP3A4 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.